On August 3, 2022 Amber Specialty Pharmacy reported that they will begin dispensing 13 Pfizer oncology products (Press release, Pfizer, AUG 3, 2022, View Source [SID1234617414]). The pharmacy’s comprehensive service model will support patients, caregivers, and oncology specialists throughout the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Pfizer portfolio of oncology products now supported by Amber Specialty Pharmacy includes:

Besponsa (inotuzumab ozogamicin)
Bosulif (bosutinib)
Braftovi (encorafenib)
Daurismo (glasdegib)
Ibrance (palbociclib)
Inlyta (axitinib)
Lorbrena (lorlatinib)
Mektovi (binimetinib)
Mylotarg (gemtuzumab ozogamicin)
Sutent (sunitinib malate)
Talzenna (talazoparib)
Vizimpro (dacomitinib)
Xalkori (crizotinib)

Amber Specialty Pharmacy is licensed to ship prescription medication to all 50 states in the U.S., as well as Puerto Rico.